Surgery and Dupilumab Compared for Nasal Polyp Care

A new study reveals how surgery and dupilumab differ in long-term recurrence risks and medication needs for adults.

Updated on Oct. 29, 2026 in Asthma

Isometric editorial illustration of a surgical tool and a medicine vial, representing a comparison of clinical treatment methods for chronic polyps. — A retrospective study comparing surgery and dupilumab for chronic nasal polyps indicates distinct long-term healthcare usage patterns between the two treatments. AI Illustration. Upload story photo >

Live Poll

Is choosing between medication and surgery for chronic sinus issues a difficult medical decision?

A retrospective study published on October 17, 2026, comparing treatment outcomes for chronic rhinosinusitis with nasal polyps found distinct patterns in healthcare usage between surgery and dupilumab patients. For those managing this condition, understanding these trade-offs is essential for long-term care planning.

Why it matters

Choosing between surgical intervention and biologic medication like dupilumab involves balancing immediate symptom relief against long-term recurrence risks. This evidence helps patients and clinicians weigh the timing of medications versus procedures for chronic nasal polyps.

A retrospective cohort study involving 12,944 patients examined outcomes for those with nasal polyps treated via endoscopic sinus surgery or dupilumab. While dupilumab patients initially required fewer antibiotics or steroids, they faced a higher risk of polyp recurrence over time.

The players

American Journal of Rhinology & Allergy

A peer-reviewed medical publication focusing on clinical and translational research related to sinus and nasal health.

The details

Researchers compared outcomes using data from 2019 to 2025, tracking how each treatment affects inflammation and structure in the nasal passages. Surgery physically removes obstructive tissue, while dupilumab works by blocking specific proteins that drive allergic inflammation. The data suggests that while medication may provide early relief from acute sinusitis symptoms, it may not address the mechanical polyp regrowth as effectively as surgery in the long term.

The study analyzed patient treatment periods occurring from July 2019 to November 2025.
Results were published in the American Journal of Rhinology & Allergy on October 17, 2026.

Health Landscape

The introduction of biologics like dupilumab has shifted the management of chronic rhinosinusitis with nasal polyps away from a surgery-first model. This study offers a necessary reality check on how these newer pharmaceutical interventions compare to established surgical practices.

If you are considering treatment for nasal polyps, discuss with your doctor how your choice of therapy might influence the likelihood of future procedures or medication reliance. It is worth tracking your own symptoms and recurrence timeline when evaluating whether a surgical or non-surgical path fits your health goals.

The takeaway

The choice between surgery and dupilumab for nasal polyps involves distinct trade-offs between short-term antibiotic use and long-term polyp recurrence risks. Keep a record of all your treatments and any symptom returns to discuss with your ENT specialist at your next follow-up appointment.